CN111132680B - 新型braf抑制剂及其用于治疗皮肤反应的用途 - Google Patents

新型braf抑制剂及其用于治疗皮肤反应的用途 Download PDF

Info

Publication number
CN111132680B
CN111132680B CN201880060593.7A CN201880060593A CN111132680B CN 111132680 B CN111132680 B CN 111132680B CN 201880060593 A CN201880060593 A CN 201880060593A CN 111132680 B CN111132680 B CN 111132680B
Authority
CN
China
Prior art keywords
compound
pharmaceutical composition
fold
mixture
erk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880060593.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111132680A (zh
Inventor
诺阿·舍拉赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lutris Pharma Ltd
Original Assignee
Lutris Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lutris Pharma Ltd filed Critical Lutris Pharma Ltd
Publication of CN111132680A publication Critical patent/CN111132680A/zh
Application granted granted Critical
Publication of CN111132680B publication Critical patent/CN111132680B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
CN201880060593.7A 2017-07-29 2018-07-26 新型braf抑制剂及其用于治疗皮肤反应的用途 Active CN111132680B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538675P 2017-07-29 2017-07-29
US62/538,675 2017-07-29
PCT/IL2018/050836 WO2019026065A2 (en) 2017-07-29 2018-07-26 NOVEL BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS

Publications (2)

Publication Number Publication Date
CN111132680A CN111132680A (zh) 2020-05-08
CN111132680B true CN111132680B (zh) 2022-02-08

Family

ID=65233550

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880060593.7A Active CN111132680B (zh) 2017-07-29 2018-07-26 新型braf抑制剂及其用于治疗皮肤反应的用途

Country Status (15)

Country Link
US (3) US10927112B2 (enExample)
EP (1) EP3661515B1 (enExample)
JP (1) JP6912667B2 (enExample)
KR (1) KR102328351B1 (enExample)
CN (1) CN111132680B (enExample)
AU (1) AU2018311538B2 (enExample)
CA (1) CA3070542C (enExample)
DK (1) DK3661515T3 (enExample)
ES (1) ES2908602T3 (enExample)
HR (1) HRP20220609T1 (enExample)
IL (1) IL272312B (enExample)
MX (1) MX383386B (enExample)
SI (1) SI3661515T1 (enExample)
WO (1) WO2019026065A2 (enExample)
ZA (1) ZA202000354B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458139B2 (en) * 2017-08-08 2022-10-04 Memorial Sloan Kettering Cancer Center Use of BRAF inhibitors for treating cutaneous reactions caused by treatment with a MEK inhibitor
MX2021009535A (es) 2019-02-12 2022-10-10 Lutris Pharma Ltd Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.
WO2022136912A1 (en) * 2020-12-24 2022-06-30 Lutris Pharma Ltd. Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions
WO2023275620A2 (en) * 2021-07-02 2023-01-05 Lutris Pharma Ltd. Use of isoquinoline-1,5-diamines for wound healing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557830B2 (en) * 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
TWI611053B (zh) 2012-02-27 2018-01-11 曾宇鳳 為先導藥物最適化之以結構為基礎的片段遷越及合成可行性之改良
KR20140011780A (ko) 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
RU2015149937A (ru) * 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
CN106535900A (zh) * 2014-05-06 2017-03-22 加利福尼亚大学董事会 使用braf抑制剂的伤口愈合
CN109069511A (zh) 2016-03-10 2018-12-21 鲁特里斯制药有限公司 Braf抑制剂用于治疗皮肤反应的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557830B2 (en) * 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use

Also Published As

Publication number Publication date
JP2020528933A (ja) 2020-10-01
ES2908602T3 (es) 2022-05-03
JP6912667B2 (ja) 2021-08-04
BR112020001935A2 (pt) 2020-07-28
ZA202000354B (en) 2024-01-31
RU2020108782A3 (enExample) 2021-09-02
WO2019026065A2 (en) 2019-02-07
US20210070757A1 (en) 2021-03-11
EP3661515B1 (en) 2022-02-23
KR20200035990A (ko) 2020-04-06
CA3070542C (en) 2021-05-18
HRP20220609T1 (hr) 2022-06-24
KR102328351B1 (ko) 2021-11-19
CA3070542A1 (en) 2019-02-07
MX383386B (es) 2025-03-13
EP3661515A2 (en) 2020-06-10
CN111132680A (zh) 2020-05-08
EP3661515A4 (en) 2021-01-06
AU2018311538B2 (en) 2021-03-25
DK3661515T3 (da) 2022-04-19
SI3661515T1 (sl) 2022-06-30
AU2018311538A1 (en) 2020-02-13
RU2020108782A (ru) 2021-09-02
US20190389862A1 (en) 2019-12-26
IL272312B (en) 2021-06-30
US11339163B2 (en) 2022-05-24
US10927112B2 (en) 2021-02-23
IL272312A (en) 2020-03-31
WO2019026065A3 (en) 2019-08-01
US20220274988A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
US20220274988A1 (en) Braf inhibitors and use thereof for treatment of cutaneous reactions
CN114667147A (zh) 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
CN105315259A (zh) 吡啶胺基嘧啶衍生物、其制备方法及应用
JP2012524814A (ja) １，２，４−チアジアゾール誘導体の安定的な局所組成物
AU2015263121A1 (en) Chemical compounds and use thereof for improving muscular quality
KR20100087298A (ko) 피부 질환의 예방 및/또는 치료제
EP4426286A1 (en) Bifunctional pi3k-alpha inhibitors and uses thereof
KR20240112283A (ko) Pi3k-알파 저해제 그리고 이의 제조 방법 및 사용 방법
CN118201917A (zh) 具有降解gspt1活性的化合物及其应用
EP3532062A1 (en) Ror-gamma modulators
CN109651377B (zh) 一种治疗癌症的化合物及其用途
JP2019519573A (ja) がんを処置するための方法
CN111249282A (zh) 癌症疗法
CN117222411B (zh) 药物组合、包含其的试剂盒及其用途
AU2024326170A1 (en) Pharmaceutical preparation of piperazine derivative, preparation method therefor, and use thereof
RU2779185C2 (ru) Новые ингибиторы braf и их применение для лечения кожных реакций
CN117136061A (zh) Sik抑制剂及其使用方法
CN104151250B (zh) 一类含苯并咪唑基团的二芳基酰胺类化合物及其合成和应用
TWI308148B (en) Novel compound of 6-methyl-3-phenethyl-3,4-dihydro-1h-quinazoline-2-thione, its preparation and a depigmentation composition containing the same as an effective component
BR112020001935B1 (pt) Novos inibidores de braf e uso destes para o tratamento de reações cutâneas
CN117582438B (zh) 吡啶类衍生物的药物组合物、制备方法及用途
JP2008019252A (ja) 色素沈着症の予防または治療用医薬組成物
HK40079301A (en) Alkenyl pyrimidine compound, preparation method therefor, and application thereof
CN109776373A (zh) 酰胺取代的吡咯烷酰胺衍生物及其用途
ZA200104275B (en) 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular CDK2.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant